Freedman SF, Hercinovic A, Wallace DK, Kraker RT, et al. Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes. Ophthalmology 2022 May 31. pii: S0161-6420(22)00408.
PMID: 35660415